OmniAb, Inc. Common Stock

VERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The com...

AI is transforming healthcare through innovative technologies like disease screening, genetic testing, antibody discovery, and drug development platforms, with several companies making significant technological advancements in medical AI applications.

VERAXA Biotech and OmniAb have entered a co-discovery alliance to develop a novel bispecific antibody drug conjugate program targeting solid tumors. The partnership combines VERAXA's ADC technology with OmniAb's antibody discovery solutions.

USANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Although U.S. stocks closed lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for mak...